Omada Health, Inc. OMDA 深 滬
已收盤 02-06 16:00:00 美东时间
11.65
-0.335
-2.80%
華盛通- 最 高12.30
- 今 開12.00
- 成交量 142.81万股
- 最 低 11.5001
- 昨 收 11.985
- 總市值 6.75亿
- 52周最高 28.40
- 市盈率 靜 --
- 換手率 2.47%
- 52周最低 11.5001
- 委 比 -8.56%
- 總股本 5790.80万
- 歷史最高 28.40
- 量 比 1.09
- 振 幅 6.67%
- 歷史最低 11.5001
- 每 手 1
- 風險率 3.48%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 潜在涨幅258.31%！Tempest Therapeutics获HC Wainwright上调评级至"买入"，目标价11美元
今日重点评级关注：HC Wainwright & Co.：上调Tempest Therapeutics评级至"买入"，目标价11美元；Guggenheim：维持Sportradar Gr"买入"评级，目标价从34美元升至35美元
01-23 19:46
Needham Reiterates Buy on Omada Health, Maintains $28 Price Target
Needham analyst Ryan MacDonald reiterates Omada Health (NASDAQ:OMDA) with a Buy and maintains $28 price target.
01-22 20:27
Omada Health Reports Preliminary Q4 2025 Revenue Of $72M-$74M; FY25 Revenue Of $256M-$258M; Total Members Reach ~886,000, Up 55% YoY
Omada Health (NASDAQ:OMDA), the virtual between-visit healthcare provider, today announced preliminary, unaudited revenue for the fourth quarter and fiscal year ended December 31, 2025, ahead of its presentation at the
01-12 22:12
美股大行评级 | 瑞穗上调英伟达、谷歌、美光科技、SanDisk多家科技股目标价；中金首予诺和诺德"跑赢大市"评级，目标价73.5美元
今日重点评级关注：Needham：维持Cartesian Therapeutics"买入"评级，目标价从40美元升至42美元；Piper Sandler：维持Acrivon Therapeutics"超配"评级，目标价从6美元升至8美元
01-12 14:09
Omada Health’s GLP-1 Behavior Change Companion Programs Help Drive Lasting, Long-Term Weight Loss
Omada Health announced results from a 12-month real-world analysis of its GLP-1 companion program, showing greater weight loss and medication persistence compared to real-world evidence. Members who stayed in the program achieved an average weight loss of 18.4% at one year, compared to 11.9% in real-world studies. Omada members using semaglutide and tirzepatide had 47% and 37% greater weight loss, respectively. The analysis also found that 67% of...
01-08 14:00
美股大行评级 | 潜在涨幅36.7%！LMRI获多家大行首予超配评级； 瑞银下调甲骨文目标价从325美元至280美元
今日重点评级关注：HC Wainwright & Co.：维持Assertio Holdings"买入"评级，目标价从3美元升至35美元；HC Wainwright & Co.：维持万达生物制药"买入"评级，目标价从20美元升至22美元
01-06 17:52
Barclays Maintains Overweight on Omada Health, Lowers Price Target to $22
Barclays analyst Saket Kalia maintains Omada Health (NASDAQ:OMDA) with a Overweight and lowers the price target from $29 to $22.
01-05 23:07
Omada Health to Participate in J.P. Morgan Healthcare Conference
Omada Health (Nasdaq: OMDA), a virtual healthcare provider specializing in cardiometabolic conditions, announced that its senior management will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco. The presentation will take place on January 14, 2026, at 9 a.m. PST, with a webcast available online at *https://investors.omadahealth.com/news-events/events*. A replay will also be accessible post-event. Omada Health serves o...
2025-12-22 14:00
Catalyst Watch: Holiday shopping data, Amazon event, and Salesforce earnings
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Read more about the events that may impact stock prices next week. Monday - December ...
2025-11-29 02:30
Omada Health to Participate in Evercore Healthcare Conference
Omada Health (Nasdaq: OMDA), a virtual between-visit healthcare provider, announced that senior management will participate in the 8th Annual Evercore Healthcare Conference in Miami, including a fireside chat on December 3, 2025, at 1:20 pm ET. The webcast will be available online at https://investors.omadahealth.com/news-events/events, with a replay following the event. Omada Health specializes in addressing cardiometabolic conditions and muscul...
2025-11-20 14:05
